OM:BIOVIC B

Stock Analysis Report

Executive Summary

Biovica International AB (publ), a biotech company, develops and commercializes blood-based biomarker assays that enhance the monitoring of cancer therapies and predict patient outcome.

Snowflake

Fundamentals

Flawless balance sheet with limited growth.

Risks

  • Biovica International is covered by less than 3 analysts.

Share Price & News

How has Biovica International's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

5.0%

OM:BIOVIC B

1.3%

SE Biotechs

1.4%

SE Market


1 Year Return

12.1%

OM:BIOVIC B

-27.9%

SE Biotechs

2.2%

SE Market

BIOVIC B outperformed the Biotechs industry which returned -27.3% over the past year.

BIOVIC B outperformed the Market in Sweden which returned 1.6% over the past year.


Share holder returns

BIOVIC BIndustryMarket
7 Day5.0%1.3%1.4%
30 Day-4.9%-7.0%6.3%
90 Day21.6%-10.7%1.5%
1 Year12.1%12.1%-27.6%-27.9%6.5%2.2%
3 Yearn/a21.7%12.0%30.7%11.2%
5 Yearn/a43.2%46.8%54.2%21.5%

Price Volatility Vs. Market

How volatile is Biovica International's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Biovica International undervalued based on future cash flows and its price relative to the stock market?

2.66x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Biovica International to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Biovica International to establish if it is available at substantial discount.


Price Based on Earnings

Biovica International is loss making, we can't compare its value to the SE Biotechs industry average.

Biovica International is loss making, we can't compare the value of its earnings to the Sweden market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Biovica International, we can't assess if its growth is good value.


Price Based on Value of Assets

Biovica International is good value based on assets compared to the SE Biotechs industry average.


Next Steps

Future Growth

How is Biovica International expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

54.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Biovica International's revenue is expected to grow significantly at over 20% yearly.

Biovica International is not considered high growth as it is expected to be loss making for the next 1-3 years.

Biovica International's revenue growth is expected to exceed the Sweden market average.

Unable to compare Biovica International's earnings growth to the Sweden market average as it is expected to be loss making during the next 1-3 years.

Unable to compare Biovica International's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Biovica International will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Biovica International performed over the past 5 years?

-29.2%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Biovica International does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Biovica International's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Biovica International's 1-year growth to the SE Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Biovica International has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Biovica International has efficiently used its assets last year compared to the SE Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Biovica International improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Biovica International's financial position?


Financial Position Analysis

Biovica International is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Biovica International's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Biovica International has no debt.

Biovica International has no debt compared to 5 years ago when it was 11.7%.


Balance Sheet

Low level of unsold assets.

Biovica International has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Biovica International has sufficient cash runway for 2.6 years based on current free cash flow.

Biovica International has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 15.4% each year.


Next Steps

Dividend

What is Biovica International's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Biovica International's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Biovica International's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Biovica International has not reported any payouts.

Unable to verify if Biovica International's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Biovica International has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Biovica International's salary, the management and board of directors tenure and is there insider trading?

2.7yrs

Average management tenure


CEO

Anders Rylander (49yo)

9.7yrs

Tenure

0

Mr. Anders Rylander serves as Chief Executive Officer of Biovica International AB (publ) since 2010. Mr. Rylander is the Founder of Arinvest and Co-Founder of Axholmen. He has been a Management Consultant  ...


Management Age and Tenure

2.7yrs

Average Tenure

48.5yo

Average Age

The tenure for the Biovica International management team is about average.


Board Age and Tenure

4.7yrs

Average Tenure

60yo

Average Age

The tenure for the Biovica International board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

Buykr10,00014 May 19
Cecilia Driving
EntityIndividual
Role
Chief Financial Officer
Chief Financial Officer
Shares1,000
Max Pricekr10.00
Buykr79,20008 May 19
Arinvest AB
EntityCompany
Shares8,000
Max Pricekr9.90
Buykr54,34008 May 19
Jesper Söderqvist
EntityIndividual
Role
Member of the Board of Directors
Director
Shares5,500
Max Pricekr9.88
Buykr53,70314 Dec 18
Anders Rylander
EntityIndividual
Role
Chief Executive Officer
CEO & Director
Shares6,034
Max Pricekr8.90
Buykr26,55014 Dec 18
Cecilia Driving
EntityIndividual
Role
Chief Financial Officer
Chief Financial Officer
Shares3,000
Max Pricekr8.85
Buykr9,70006 Nov 18
Karin Mattsson
EntityIndividual
Shares1,000
Max Pricekr9.70
Buykr30,20205 Nov 18
Arinvest AB
EntityCompany
Shares3,044
Max Pricekr9.92

Ownership Breakdown


Management Team

  • Cecilia Driving (48yo)

    Chief Financial Officer

    • Tenure: 2.7yrs
  • Jarl Jungnelius (68yo)

    Director & Senior Oncology Advisor

    • Tenure: 5.7yrs
  • Anders Rylander (49yo)

    CEO & Director

    • Tenure: 9.7yrs
  • Adam Germunder (35yo)

    Operations Director

    • Tenure: 1.8yrs

Board Members

  • Lars Holmqvist (60yo)

    Chairman of the Board

    • Tenure: 0.5yrs
  • Maria Holmlund (63yo)

    Director

    • Tenure: 3.7yrs
  • Jarl Jungnelius (68yo)

    Director & Senior Oncology Advisor

    • Tenure: 5.7yrs
  • Anders Rylander (49yo)

    CEO & Director

    • Tenure: 9.7yrs
  • Jesper Söderqvist (53yo)

    Director

    • Tenure: 6.7yrs
  • Henrik Osvald

    Director

    • Tenure: 0.08yrs

Company Information

Biovica International AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Biovica International AB (publ)
  • Ticker: BIOVIC B
  • Exchange: OM
  • Founded: 2009
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: kr273.451m
  • Shares outstanding: 23.57m
  • Website: https://biovica.com

Number of Employees


Location

  • Biovica International AB (publ)
  • Dag Hammarskjölds väg 54B
  • Uppsala Science Park
  • Uppsala
  • Uppsala County
  • 752 37
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BIOVIC BOM (OMX Nordic Exchange Stockholm)YesB SharesSESEKMar 2017

Biography

Biovica International AB (publ), a biotech company, develops and commercializes blood-based biomarker assays that enhance the monitoring of cancer therapies and predict patient outcome. It primarily focuse ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/17 22:53
End of Day Share Price2019/09/17 00:00
Earnings2019/07/31
Annual Earnings2019/04/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.